Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine
Vaccine administration may be involved in the development of some central nervous system demyelinating diseases. The COVID-19 vaccine is being administered to the entire population, but to date, little association between vaccination and the risk of developing multiple sclerosis (MS) has been suggested, and only a few case reports have been published. Here, we present a 40-year-old woman who developed cervical myelitis after receiving the COVID-19 vaccine. Myelitis was considered the initial clinical manifestation of MS.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Juichi Fujimori, Kouichi Miyazawa, Ichiro Nakashima Tags: Short Communication Source Type: research
More News: Allergy & Immunology | Brain | COVID-19 | Multiple Sclerosis | Neurology | Pfizer | Vaccines